NDA Partners LLC: A Development Partner to Biopharmaceutical Investors and Companies

Former Head of UK Medicines & Healthcare Products Regulatory Agency (MHRA) Sir Alasdair Breckenridge Joins NDA Partners

Madison, Virginia (AUGUST 14, 2013) - Carl Peck, MD, Chairman of NDA Partners LLC (NDAP), today announced that Sir Alasdair Breckenridge, former head of the UK Medicines & Healthcare Products Regulatory Agency (MHRA) has joined NDA Partners as a partner in the firm. MHRA is the Department of Health agency responsible for regulating all medicines and medical devices marketed in the UK.

In his role at NDA Partners, Sir Alasdair will provide leadership for the firm's expanding EU operations and expert consulting to its worldwide client base in complex and rapidly evolving topics such as health care policy, health technology assessment, reimbursements, EU clinical trials, global product development, global regulatory strategies, benefit-risk assessment, and bioethics. "Alasdair's decades of experience at the forefront of drug development science and deep understanding of the global regulatory environment will be a tremendous asset for our clients as they seek the best available advice to guide their development programs", said Dr Peck. "We look forward to Alasdair’s active involvement on our team and with our global client base".

Sir Alasdair has a long and prestigious career in drug development science and regulatory affairs. He was the first Chair of MHRA when it was formed in 2003 and retained this position until his retirement from the Agency in 2012. During his tenure at MHRA, he served as the first Chair of the Department of Health's Emerging Science and Bioethics Advisory Committee (ESBAC), an organization responsible for providing advice to UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications. He was a member of the Medical Research Council, worked closely on several programs of the European Union, the World Health Organization and the International Union of Pharmacology, and was Chair of the Committee on Safety of Medicines. Prior to MHRA, he was Professor of Clinical Pharmacology at the University of Liverpool and a member and then Chairman of local and regional health authorities in the north-west of England, including Chairman of the North West Regional Office. Sir Alasdair is a clinical pharmacologist and after training at the Royal Postgraduate Medical School, he was appointed to the Chair of Clinical Pharmacology at the University of Liverpool. Sir Alasdair was knighted in 2004.

About NDA Partners
NDAP is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms and investment funds. The highly experienced Principals and Premier Experts of NDA Partners include two former FDA Center Directors and an extensive international team of former pharmaceutical and medical device industry senior executives and regulators. Services include expert consulting, product development planning, regulatory strategy, advisory boards, product assessments and due diligence, litigation and patent support, and associated support projects.

Contact
Earle Martin, General Manager
+01 540-923-4582
MartinEarle@ndapartners.com